The original title of our paper was inaccurate in referring to ‘Venom from Cuban Blue Scorpion’ and did not accurately reflect that we investigated the effects of the commercially-available product Vidatox 30 CH on hepatocellular carcinoma.
The title has been changed from:
“Venom from Cuban Blue Scorpion has tumor activating effect in hepatocellular carcinoma”.
to:
“Vidatox 30 CH has tumor activating effect in hepatocellular carcinoma”.
Additional information
The online version of the original article can be found at 10.1038/srep44685
Rights and permissions
This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
About this article
Cite this article
Giovannini, C., Baglioni, M., Baron Toaldo, M. et al. Erratum: Corrigendum: Vidatox 30 CH has tumor activating effect in hepatocellular carcinoma. Sci Rep 7, 46920 (2017). https://doi.org/10.1038/srep46920
Published:
DOI: https://doi.org/10.1038/srep46920
This article is cited by
-
Brivanib in combination with Notch3 silencing shows potent activity in tumour models
British Journal of Cancer (2019)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
